A：Stryker's second quarter results demonstrated the strength of their broad product portfolio and the resiliency of their teams, continuing the recovery from the cybersecurity incident with ramped overall production to support patient sales. There was a med surge in neurotechnology and orthopedics businesses, and geographically, U.S. organic sales growth of 9% was achieved with double-digit growth from medical trauma, extremities, and end businesses, and high single-digit growth in orthopedics and instruments. Internationally, 8.9% organic sales growth was driven by strong performances in multiple countries. The company delivered adjusted EPS growth of 17.9%, reflecting improved gross margins and operational execution.

A：Stryker faced supply disruptions in their peripheral vascular business, resulting in a meaningful backorder situation with lost sales. The company addressed the issue, and backorders are expected to reach a manageable level by the end of Q3. Additionally, while capital delivery was a key driver of growth and demand remained strong, the elevated backlog expected to continue through the remainder of the year reflects the ongoing strength in the hospital capital environment.

A：Stryker highlighted several key products and achievements: Best ever second-quarter performance for ACO installation in the U.S. and internationally with trending upward utilization rates; The 20th anniversary of MAKO, which has evolved into a multi-specialty robotic platform; The full commercial launch of MAKO RPS in the U.S., expanding the company's robotics portfolio; Rapid full commercial launches of triathlon gold and triathlon medial stabilized inser; Approval of patient-specific planning and guides for the new Encompassed whole ankle replacement system; And the limited launch of the PGA trauma plating system in Europe, with a full commercial launch expected in the fourth quarter. Stryker also mentioned the upcoming launch of the Soca II ultrasonic aspirator.

A：Pricing was flat, foreign currency had a slightly favorable impact on sales, and the current quarter had the same number of selling days compared to the prior year. These factors, along with strong sales growth, a continued focus on operational excellence, and a net benefit in the quarter from tariff-related costs, contributed to Stryker's adjusted earnings per share growth of 3.59 dollars, up 56 cents or 17.9% from the same quarter last year.

A：Stryker's Neurotechnology segment delivered organic sales growth of 9.2%, with U.S. organic growth of 8.9% and international organic growth of 10.5%. U.S. organic sales rose 8.4% against the prior year. Growth was robust in the interventional spine and pain portfolio and strong in the surgical technologies business, which includes Neptune waste management, smoke evacuation, and surgical products endoscopy.

A：Vascular US organic sales declined 6.7% due to operational disruptions in peripheral vascular, as mentioned by Kevin, partially offset by solid growth in the MRI portfolio driven by the surpass elites and neurotechnology organic sales growth of 10.5% across endoscopy, medical, and instruments.

A：US orthopedics delivery of organic sales growth was attributed to the continued adoption of Maco for robotic-assisted knee procedures and momentum from cementless新产品. Internationally, robust Maco installations contributed to orthopedics organic sales growth of 7.5%, with strength in knee, orthopedic, and trauma extremities.

A：The adjusted gross margin was 66%, which was 170 basis points favorable to the second quarter of 2025. It was influenced by the net tariff benefit and an improvement in business and operating income due to lower adjusted selling, general, and administrative (SG&A) as a percentage of sales.

A：The second quarter had an adjusted effective tax rate of 16.5%, which reflected the impact of geographic mix and certain discrete tax items. The full year effective tax rate is expected to be in the range of 15% to 16%.

A：The updated guidance for the full year anticipates organic net sales growth in the range of 8.2% to 9.3%, and adjusted net earnings per share to be in the range of $14.95 to $15.10. The full year sales guidance reflects a modestly positive pricing impact and a slightly favorable impact of sales and earnings per share should rates hold current levels.

A：The factors affecting the company's ability to increase revenue in the back half of the year include market strength in procedures, consistent expectations, potential improvements that could provide a tailwind, and the ability to ramp products, including new launches, ahead of projections.

A：The company believes it can't fully benefit from the quarter's positive results in the full year guidance due to the carryover costs from the cyber perspective, the loss absorption from manufacturing, and the It costs related to remediation that will offset the benefits.

A：Revenue growth is being driven by continued momentum across all businesses and strong demand for capital products. The guidance suggests that the second half of the year could show a significant uptick in revenue, with production ramping up to support the higher volumes.

A：The revenue variability in the first quarter was due to the variability of different businesses and some areas experiencing catch-up revenue. The company addressed supply issues by taking on the pain of supply destruction and adjusting production to meet the strong demand, with a particular mention of challenges in the medical business segment due to backlogs from a long production pause.

A：The company is managing through volatility by recognizing the continued strong demand across various businesses despite temporary production setbacks. They expect overall healthiness of the business and a return to strong performance in procedures, with the acknowledgment of potential volatility in Q3 and Q4. They remain positive about the full-year outlook.

A：The procedure volumes are stable and the demand is strong and healthy. The CapEx environment is characterized as healthy with no concerns about the procedures in which the company participates. They have an elevated backlog and have experienced a record month in MACO sales. However, there has been a slight slowdown in Europe, but not in the US or other markets. These factors are expected to contribute to the company's performance.

A：The revenue guidance was updated by raising the lower end of the sales guidance from 8 to 8.3, which indicates confidence in achieving the targeted organic growth of about 11% in the second half of the year. This growth is driven by strong orders for capital products and the ability to ramp up production. The company is confident in meeting the guidance based on the performance of capital products and their backlog.

A：The company plans to manage production and sales by focusing on the ramp-up of production for capital products and getting them out the door. This strategy is expected to provide a steady cadence across both quarters, as production has been consistent since April, offering visibility into orders and surgery schedules.

A：Factors potentially impacting the EPS guidance in the back half of the year include additional expenses and margin impacts from excess production. The company is guiding for lower EPS in the fourth quarter, which may result from these factors, but they are also expecting a healthy demand across their businesses.

A：The company is committed to increasing off margin by 150 basis points over the course of three years.

A：The company is dealing with several moving parts, including cyber events that led to manufacturing shutdowns, idle costs, and remediation efforts; pressures on oil and other raw materials; and managing tariffs. They are focusing on delivering on the top line and expect it to flow through to ETPs.

A：Future physician reimbursement for large joint replacements may be impacted by proposed rules, shifting sites of care with orthopedic procedures, and overall reimbursement pressures. However, the demand for joint replacement procedures is anticipated to continue without change due to an aging population and increasing activity levels.

A：The U.S. orthopedic numbers, specifically the U.S. TIP number, might show underlying growth challenges because of a large prior year comparable with 8% growth last year. One quarter does not necessarily indicate a trend, and nothing major has changed in terms of underlying market conditions.

A：The supply disruption caused a significant backlog at one plant due to issues with a particular plant. This backlog was elevated but was expected to be brought down to a manageable level by the end of Q3. Sales are expected to grow in Q3 and Q4, but it will take some time for the sales force to stabilize and recover from the backlog.

A：The key assumptions underpinning the company's strong outlook for the second half of the year include the strength of the order book, the momentum in the business, capital conversion, and backlog realization. They are confident in their ability to capitalize on these strengths across all capital businesses and believe in the potential of products like Maco for joint replacement and RPA.

A：The early feedback on the Mako RPS has been outstanding, with surgeons finding it easy to use and enjoying the experience. The feedback is positive, especially regarding how the handheld robot performs. With plans to ramp up conversions, particularly among surgeons interested only in total knee procedures, the impact of Mako RPS is anticipated to be significant in the future.

A：The factors that could potentially impact the ability to make enough product for the significant ramp in production needed for the back half of the year are primarily related to manufacturing capacity and ensuring the capital issues are accounted for in the guidance provided.

A：Business was lost during the period referred to as the 'perioperative vascular' because sales of capital equipment were impacted by the prioritization of products following an emergent situation. The company addressed this issue by implementing an allocation process, prioritizing high-volume, loyal customers, and fully ramping up their sales force which was not previously stable or fully operational.

A：The current strategy regarding capital deployment and M&A is to continue prioritizing M&A opportunities that drive future growth. However, the company has also decided to return shareholder value by potentially engaging in share buybacks. This is reflected in the company's approach to capital deployment by having a prior approval from the board for a billion dollars available for share buybacks in the second half of the year, depending on deal flow and valuation of shares.

A：The company's backlog and order book have not been significantly impacted by the concerns from hospitals or the cancellation of procedures. As of the last quarter, there were zero cancellations, and the company's teams are capable of handling slight delays in manufacturing. The company feels good about the integrity of the capital business based on customer advance ordering patterns and the ability to manage backlogs effectively.

A：The company's outlook for cash flow is robust, indicating a significant improvement from six years ago. This strength allows the company to pursue M&A deals and begin conducting share buybacks while still maintaining a strong amount of firepower for future acquisitions. The company is disciplined in its approach to M&A, focusing on the right pricing, and is committed to executing deals despite current valuations making share buybacks an opportune strategy as well.

A：The hospital system feedback has been positive, with hospitals looking at implementing the company's solutions, and the business unit is receiving great feedback.

A：The hospital business is currently experiencing steady growth with projects like construction, rebuilding, and renovations. There is an increased interest in this trend globally, particularly in Europe.

A：The IVL product is expected to be introduced above the knee in the peripheral vascular market, and feedback from customers has been positive. There's a chance the product could be sold before the end of the year, pending FDA approval. A coronary indication trial has commenced, but it will take some time, likely longer than six months to a year.

A：The company plans to continue to broaden its product offerings with other technologies to address the same call points served by the acquired businesses, following a strategy of a diversified product portfolio with a strong demand in the market.

A：The impact of the supply issue on the company's financial results in the second quarter was roughly in the ballpark of 50 to 75 basis points, which was one of the factors that contributed to the revenue recognition and procedural recovery in Q2.

A：The mechanical flow market is facing supply headwinds and intense competition but is also supported by new data and upcoming trials. The company is focused on resolving internal supply chain issues to return to double-digit growth and is optimistic about upcoming data that could further boost market growth. Positioning the mechanical flow market alongside IVL and peripheral vascular assets is a key focus area for growth.

A：The timing and pace of recent product launches have not been significantly impacted by the manufacturing disruption. The company has successfully launched products in both hospitals and ambulatory surgical centers (ASCs), focusing more on competitive users initially. Although some launches were slightly delayed due to lost production time, the demand remains very good, and the company is ramping up production. Future plans include the launch of new products in the second half, which will be an extra catalyst for growth.